Assessment of retinal vascular network in amnestic mild cognitive impairment by optical coherence tomography angiography.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
23
02
2020
accepted:
16
05
2020
entrez:
4
6
2020
pubmed:
4
6
2020
medline:
22
8
2020
Statut:
epublish
Résumé
To assess the presence of retinal vascular network abnormalities in amnestic mild cognitive impairment (aMCI) patients and healthy subjects (HS) through optical coherence tomography angiography (OCTA). OCTA and SD-OCT were performed in aMCI patients and cognitive normal HS. A complete neuropsychological evaluation was performed. Differences in vessel density (VD) in each retinal vascular plexus and in foveal avascular zone (FAZ) were evaluated with linear mixed model after correction for age, sex and disease duration. Twenty-seven aMCI patients (10 Single domain aMCI, 17 Multidomain aMCI) and 29 HS were enrolled. aMCI patients showed a statistically significant reduced VD in superficial capillary plexus (SCP), deep capillary plexus (DCP) and an increased FAZ compared to controls. When aMCI patients were divided in single domain (SD) and multiple domains (MD) aMCI, SD aMCI showed no VD differences in SCP, DCP and Radial Peripapillary Capillary, while the FAZ area was significantly larger compared to controls. In MD aMCI, VD values were lower and FAZ was increased compared to controls. Comparing both aMCI groups, MD aMCI showed a significant reduction in VD values of SCP. No correlation was found between mini mental state examination (MMSE) scores and OCTA parameters. OCTA is able to detect changes in retinal microvascular network in early cognitive deficits and, the most sensitive alteration seems to be the enlargement of the FAZ. This non-invasive tool provides useful information on retinal involvement patterns in MCI diagnosis and follow up. Vascular network impairment seems to be related to the number of domains affected and not to MMSE.
Identifiants
pubmed: 32492054
doi: 10.1371/journal.pone.0233975
pii: PONE-D-20-04966
pmc: PMC7269252
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0233975Déclaration de conflit d'intérêts
R. Lanzillo received personal fees for public speaking or consultancy from Merck, Novartis, Biogen, Roche, Genzyme, Teva and Almirall. All other authors declare no conflict of interest. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Références
Br J Ophthalmol. 2018 Feb;102(2):233-237
pubmed: 28600299
JAMA Ophthalmol. 2018 Nov 1;136(11):1242-1248
pubmed: 30352114
Lancet. 2002 Dec 14;360(9349):1963-5
pubmed: 12493278
Ann Neurol. 2005 Jun;57(6):789-94
pubmed: 15929050
Transl Vis Sci Technol. 2018 Oct 01;7(5):20
pubmed: 30280005
J Clin Exp Neuropsychol. 2012;34(1):11-34
pubmed: 22053873
Dev Ophthalmol. 2016;56:6-12
pubmed: 27022989
Ital J Neurol Sci. 1987 Dec;8(6):539-48
pubmed: 3429213
J Neuroophthalmol. 2018 Sep;38(3):292-298
pubmed: 29040211
Cochrane Database Syst Rev. 2015 Mar 05;(3):CD010783
pubmed: 25740785
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
Invest Ophthalmol Vis Sci. 2007 May;48(5):2285-9
pubmed: 17460292
PLoS One. 2020 Mar 20;15(3):e0230260
pubmed: 32196538
Retina. 2015 Nov;35(11):2188-95
pubmed: 26469536
Neurology. 1998 Jun;50(6):1563-71
pubmed: 9633695
Nat Rev Neurosci. 2017 Jul;18(7):419-434
pubmed: 28515434
J Alzheimers Dis. 2011;26 Suppl 3:123-33
pubmed: 21971457
Brain. 1962 Dec;85:665-78
pubmed: 14026018
Opt Express. 2012 Feb 13;20(4):4710-25
pubmed: 22418228
Retina. 2015 Nov;35(11):2332-8
pubmed: 26502008
PLoS One. 2017 Nov 27;12(11):e0188572
pubmed: 29176837
Alzheimers Dement. 2011 May;7(3):270-9
pubmed: 21514249
Angiogenesis. 2004;7(1):75-85
pubmed: 15302999
Br J Ophthalmol. 2020 Feb;104(2):157-161
pubmed: 31118186
Nat Rev Neurol. 2013 Jan;9(1):44-53
pubmed: 23165340
Retina. 2018 Dec;38(12):2277-2284
pubmed: 29068912
Am J Ophthalmol. 2016 Nov;171:75-83
pubmed: 27590118
Invest Ophthalmol Vis Sci. 2011 Feb 01;52(1):625-34
pubmed: 20861480
Front Neurol. 2019 Aug 16;10:889
pubmed: 31474933
J Curr Ophthalmol. 2017 Jul 29;29(4):293-299
pubmed: 29270477
J Neuroimaging. 2014 Nov-Dec;24(6):590-594
pubmed: 24593247
PLoS One. 2019 Apr 2;14(4):e0214685
pubmed: 30939178
Nat Rev Neurosci. 2011 Nov 03;12(12):723-38
pubmed: 22048062
Ital J Neurol Sci. 1987 Dec;Suppl 8:1-120
pubmed: 3330072
Am J Alzheimers Dis Other Demen. 2013 Sep;28(6):551-9
pubmed: 23813612
Ophthalmology. 2019 Dec;126(12):1675-1684
pubmed: 31358386
Graefes Arch Clin Exp Ophthalmol. 2013 Jan;251(1):129-37
pubmed: 22684903
Eur Neurol. 1996;36(6):378-84
pubmed: 8954307
J Anat. 2005 Apr;206(4):319-48
pubmed: 15817102
Graefes Arch Clin Exp Ophthalmol. 2017 Sep;255(9):1787-1793
pubmed: 28631244
JAMA. 2014 May 14;311(18):1901-11
pubmed: 24825645
Am J Ophthalmol. 2018 Feb;186:25-31
pubmed: 29169882
Eye Vis (Lond). 2018 May 12;5:11
pubmed: 29796403
Acta Psychiatr Scand. 2009 Apr;119(4):252-65
pubmed: 19236314
JAMA Intern Med. 2015 Sep;175(9):1450-8
pubmed: 26052687
Neurology. 2007 Jan 23;68(4):288-91
pubmed: 17242334
J Alzheimers Dis. 2015;45(1):45-56
pubmed: 25428254
Ophthalmol Retina. 2019 Jun;3(6):489-499
pubmed: 31174670
Prog Retin Eye Res. 2017 Sep;60:66-100
pubmed: 28760677
Neurol Res. 2004 Jul;26(5):573-8
pubmed: 15265277